Pomegranate Oil-Seaweed Mix
May Help You Lose 10 Pounds
A blend of pomegranate oil and brown seaweed extract may produce
weight loss of about five kilos, as well as improvements in liver
health, says new study.
The new ingredient, marketed under the brand name Xanthigen,
noted improvements in women with healthy livers and those suffering
from non-alcoholic fatty liver disease (NAFLD), according to findings
of a double-blind, randomised, placebo-controlled study with obese
NAFLD, almost unknown over two decades ago, is the most common
liver disease in the US. Affecting over 40 million adults in the
US alone, its prevalence is expected to grow worldwide as nations
become increasingly obese.
The ingredient is a patent-pending, synergistic composition of
pomegranate oil standardized for punicic acid and brown seaweed
extract standardized for fucoxanthin.
The results of Xanthigen-600/2.4 mg trial indicate that
the formula (300 mg PSO plus 300 mg brown seaweed extract containing
2.4 mg fucoxanthin) and its individual components have clinically
relevant anti-obesity properties in reducing the body weight,
body fat and liver fat content in non-diabetic obese female volunteers,
wrote the researchers, led by Dr Musa Abidov from the Russian
Academy of Natural Sciences.
Xanthigen-600/2.4 mg was particularly effective in reducing
liver fat content in participants diagnosed with NAFLD.
The findings are published in the journal Diabetes, Obesity and
With the World Health Organization estimating that by 2015, there
will be more than 1.5 billion overweight consumers, incurring
health costs beyond $117 billion per year in the US alone, the
opportunities for a scientifically-substantiated weight management
food product are impressive.
The market for food, beverage and supplement weight management
products is already valued at $3.64bn (2009 figures) in the US,
according to Euromonitor. In Western Europe, the market was worth
$1.3bn in 2009.
Russian scientists, in collaboration with the late Dr Zakir Ramazanov,
recruited 151 obese, non-diabetic volunteers. Three-quarters of
the women had NAFLD, while the others had normal liver function.
Participants from both groups were randomly assigned to receive
either placebo or a daily dose of 600mg of Xanthigen for 16 weeks.
Diets were restricted to 1800 kcal daily, comprised of 50 per
cent carbohydrates, 30 per cent protein, and 20 per cent fat.
Results showed that body weight was significantly reduced by
an average of 5.5 kg in people in the NAFLD group and 4.9 kg in
the normal liver function group. Women in the placebo group lost
an average of 1.4 kilos. In addition, women with NAFLD experienced
improvements in waist circumference, body and liver fat content,
liver enzymes, and serum triglycerides.
A second study with women from the NAFLD group only and difference
doses of the ingredient, found that daily doses of 400mg may significantly
increased resting energy expenditure, compared to placebo.
To the best of our knowledge, this trial is the first clinical
evidence reporting the anti-obesity effect of Xanthigen, with
special relevance to obese patients with NAFLD and elevated indices
of chronic inflammation, wrote the researchers.
Xanthigen may reduce body weight and body fat in part due
to the stimulation of resting energy expenditure, but also due
to the broad anti-inflammatory and metabolism normalizing actions.
This study suggests that pomegranate oil may aid in promoting
the resting energy expenditure -stimulating action of fucoxanthin,
The ingredient is owned by Spains Polifenoles Naturales
SL (Polinat) and distributed exclusively in the US by PL Thomas.
Source: Diabetes, Obesity and Metabolism
January 25, 2010